
Sign up to save your podcasts
Or
Sam Altman is backing Merge Labs, a new brain-computer interface venture exploring a gene therapy approach to connect human brains with AI. The company is considering genetically modifying brain cells to respond to ultrasound, enabling a less invasive implant system. Merge is currently raising $250 million at an $850 million valuation, with major backing expected from OpenAI’s venture arm. This move positions Altman in direct competition with Elon Musk’s Neuralink, which uses electrode-based implants. Merge’s approach combines sonogenetics and embedded ultrasound hardware, aiming for high-bandwidth communication between thought and AI systems. Altman is co-founding the project but won’t take a day-to-day role or personally invest.
3.6
247247 ratings
Sam Altman is backing Merge Labs, a new brain-computer interface venture exploring a gene therapy approach to connect human brains with AI. The company is considering genetically modifying brain cells to respond to ultrasound, enabling a less invasive implant system. Merge is currently raising $250 million at an $850 million valuation, with major backing expected from OpenAI’s venture arm. This move positions Altman in direct competition with Elon Musk’s Neuralink, which uses electrode-based implants. Merge’s approach combines sonogenetics and embedded ultrasound hardware, aiming for high-bandwidth communication between thought and AI systems. Altman is co-founding the project but won’t take a day-to-day role or personally invest.
227,747 Listeners
4,991 Listeners
32 Listeners
341 Listeners
4,705 Listeners
394 Listeners
17,089 Listeners
9,812 Listeners
4,265 Listeners
532 Listeners
61 Listeners
150 Listeners
557 Listeners
148 Listeners
16,864 Listeners
25 Listeners
1 Listeners